PTC Therapeutics reported $109.33M in Stock for its fiscal quarter ending in September of 2026.





Stock Change Date
Acadia Pharmaceuticals USD 40.36M 68.31M Sep/2026
Alnylam Pharmaceuticals USD 105.91M 8.8M Sep/2026
Amgen USD 6.39B 169M Sep/2026
BioCryst Pharmaceuticals USD 13.74M 7.68M Sep/2026
Biogen USD 2.22B 159.9M Sep/2026
BioMarin Pharmaceutical USD 1.8B 13.54M Sep/2026
Cytokinetics USD 807K 427K Sep/2026
Daiichi Sankyo JPY 733.05B 40.68B Jun/2026
Gilead Sciences USD 1.9B 57M Sep/2026
Incyte USD 134.25M 21.71M Sep/2026
Ionis Pharmaceuticals USD 28.58M 22.26M Sep/2026
Karyopharm Therapeutics USD 4.04M 72K Dec/2025
Novartis USD 6.1B 116M Sep/2026
Pfizer USD 10.02B 77M Sep/2026
PTC Therapeutics USD 109.33M 17.98M Sep/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Roche Holding CHF 7.6B 9M Jun/2025
Sarepta Therapeutics USD 876.12M 28.15M Sep/2026
TG Therapeutics USD 194.32M 46.35M Sep/2026
Ultragenyx Pharmaceutical USD 59M 0 Sep/2026
Vertex Pharmaceuticals USD 2.25B 480.2M Sep/2026